BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 1,115 Shares of Company Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Lee sold 1,115 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $400.82, for a total value of $446,914.30. Following the transaction, the senior vice president directly owned 455 shares of the company’s stock, valued at $182,373.10. This trade represents a 71.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, September 30th, Chan Lee sold 1,115 shares of BeOne Medicines stock. The shares were sold at an average price of $375.00, for a total value of $418,125.00.
• On Tuesday, August 11th, Chan Lee sold 2,666 shares of BeOne Medicines stock. The stock was sold at an average price of $360.00, for a total value of $959,760.00.

BeOne Medicines Stock Up 2.5%

NASDAQ:ONC opened at $417.33 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $420.00. The firm has a market capitalization of $45.82 billion, a price-to-earnings ratio of 66.51 and a beta of 0.63. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average price is $364.50 and its two-hundred day moving average price is $326.72.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.64 EPS for the quarter, beating the consensus estimate of $2.34 by $1.30. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on ONC shares. Citizens Jmp upped their price target on shares of BeOne Medicines from $405.00 to $463.00 and gave the stock a “market outperform” rating in a research report on Friday. Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Royal Bank Of Canada lifted their price objective on shares of BeOne Medicines from $459.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday. Jefferies Financial Group restated a “buy” rating and set a $470.00 price objective on shares of BeOne Medicines in a research note on Thursday. Finally, Weiss Ratings raised shares of BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $436.92.

Institutional Trading of BeOne Medicines

A number of hedge funds have recently made changes to their positions in the business. First Trust Advisors LP increased its holdings in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Jennison Associates LLC raised its stake in BeOne Medicines by 102.1% in the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock valued at $45,871,000 after acquiring an additional 78,027 shares during the period. Renaissance Technologies LLC bought a new stake in BeOne Medicines in the 1st quarter valued at $19,438,000. SEB Asset Management AB acquired a new stake in BeOne Medicines during the 1st quarter valued at $16,653,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in BeOne Medicines by 96.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 110,586 shares of the company’s stock valued at $32,841,000 after purchasing an additional 54,260 shares during the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.